An open label, Phase IV Multicentric Single Arm Study to Assess the Safety and Efficacy of Croma Ophthalmic Solution Containing Sodium Cromoglycate (40 mg/ml) and Tetrahydrozoline Hydrochloride (0.5 mg/ml) in Subjects with Chronic Allergic Conjunctivitis and Hay Fever (Seasonal)

An open label, Phase IV Multicentric Single Arm Study to Assess the Safety and Efficacy of Croma Ophthalmic Solution Containing Sodium Cromoglycate (40 mg/ml) and Tetrahydrozoline Hydrochloride (0.5 mg/ml) in Subjects with Chronic Allergic Conjunctivitis and Hay Fever (Seasonal)

2020-07-04